Dalton Greiner Hartman Maher & Co. increased its position in shares of Parexel International Corp. (NASDAQ:PRXL) by 87.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 447,854 shares of the company’s stock after buying an additional 209,116 shares during the period. Parexel International Corp. comprises about 2.0% of Dalton Greiner Hartman Maher & Co.’s holdings, making the stock its largest position. Dalton Greiner Hartman Maher & Co. owned 0.84% of Parexel International Corp. worth $31,103,000 as of its most recent filing with the SEC.

Several other hedge funds also recently added to or reduced their stakes in PRXL. UBS Group AG raised its stake in Parexel International Corp. by 16.1% in the first quarter. UBS Group AG now owns 2,498,512 shares of the company’s stock worth $156,732,000 after buying an additional 346,000 shares during the last quarter. State Street Corp raised its stake in Parexel International Corp. by 1.7% in the first quarter. State Street Corp now owns 1,749,294 shares of the company’s stock worth $109,733,000 after buying an additional 28,826 shares during the last quarter. BlackRock Institutional Trust Company N.A. raised its stake in Parexel International Corp. by 3.7% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 1,609,544 shares of the company’s stock worth $101,208,000 after buying an additional 57,728 shares during the last quarter. FMR LLC raised its stake in Parexel International Corp. by 122.1% in the second quarter. FMR LLC now owns 1,001,051 shares of the company’s stock worth $62,946,000 after buying an additional 550,338 shares during the last quarter. Finally, Aberdeen Asset Management PLC UK raised its stake in Parexel International Corp. by 25.3% in the second quarter. Aberdeen Asset Management PLC UK now owns 998,811 shares of the company’s stock worth $62,806,000 after buying an additional 201,812 shares during the last quarter. Institutional investors own 95.59% of the company’s stock.

Institutional Ownership by Quarter for Parexel International Corp. (NASDAQ:PRXL)

Parexel International Corp. (NASDAQ:PRXL) traded up 0.36% during midday trading on Thursday, reaching $67.74. The company’s stock had a trading volume of 75,684 shares. Parexel International Corp. has a 12-month low of $56.00 and a 12-month high of $71.13. The firm has a market cap of $3.60 billion, a price-to-earnings ratio of 23.69 and a beta of 0.92. The company’s 50-day moving average is $68.48 and its 200 day moving average is $64.85.

Parexel International Corp. (NASDAQ:PRXL) last announced its earnings results on Wednesday, August 3rd. The company reported $0.94 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.93 by $0.01. The business earned $538.60 million during the quarter, compared to analyst estimates of $532.41 million. Parexel International Corp. had a return on equity of 33.29% and a net margin of 6.44%. The company’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.79 earnings per share. Equities analysts forecast that Parexel International Corp. will post $3.92 earnings per share for the current year.

PRXL has been the topic of a number of research analyst reports. Jefferies Group upped their target price on Parexel International Corp. from $70.00 to $72.50 and gave the stock a “hold” rating in a research note on Friday, August 5th. Citigroup Inc. upped their target price on Parexel International Corp. from $74.00 to $80.00 and gave the stock a “buy” rating in a research note on Friday, August 5th. Deutsche Bank AG upped their target price on Parexel International Corp. from $65.00 to $71.00 and gave the stock a “hold” rating in a research note on Friday, August 5th. Credit Suisse Group AG initiated coverage on Parexel International Corp. in a research note on Monday, June 20th. They issued an “outperform” rating and a $75.00 target price on the stock. They noted that the move was a valuation call. Finally, Evercore ISI restated a “buy” rating and issued a $78.50 target price (up from $71.00) on shares of Parexel International Corp. in a research note on Friday, August 5th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $71.75.

In other news, SVP Joshua Schultz sold 2,500 shares of the company’s stock in a transaction on Tuesday, August 9th. The stock was sold at an average price of $68.64, for a total transaction of $171,600.00. Following the transaction, the senior vice president now directly owns 5,168 shares of the company’s stock, valued at $354,731.52. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 2.70% of the company’s stock.

About Parexel International Corp.

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company, which provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology products and services to the pharmaceutical, biotechnology and medical device industries across the world.

5 Day Chart for NASDAQ:PRXL

Receive News & Stock Ratings for Parexel International Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Parexel International Corp. and related stocks with our FREE daily email newsletter.